Evaluating gene expression changes in children on antipsychotic medications
Official title: Pilot Study of Transcriptomic Alterations Associated with Antipsychotic-induced Metabolic Disorders in Children and Adolescents
Run by IRCCS Eugenio Medea · NCT06814314 · Data updated 2026-11-12
This study is trying to see how antipsychotic medications affect the genes of children and teens with metabolic disorders, compared to those who don't take these medications, to find early signs of possible health issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 17 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | IRCCS Eugenio Medea Academic / other |
| Locations | 1 site (Bosisio Parini, LC) |
| Status | Recruiting |
| Started | April 30, 2023 |
| Main results expected | May 2026 |
| Study ends | May 2026 |
| Registry record updated | February 7, 2025 |
| Trial ID | NCT06814314 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 5-17 who are either using antipsychotics with metabolic disorders, using antipsychotics without metabolic disorders, or not using antipsychotics but have metabolic disorders.
✕Probably not a fit
Patients with diagnosed genetic conditions that affect energy metabolism or nutrition may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the transcriptomic profiles of children and adolescents aged 5-17 who are undergoing treatment with antipsychotic drugs and exhibit metabolic disorders. It will compare these profiles with those of similar patients who do not use antipsychotics but have metabolic disorders, as well as those who use antipsychotics without metabolic disorders. The goal is to identify distinct transcriptomic markers that could serve as early indicators of metabolic complications due to antipsychotic treatment, potentially improving management strategies for these therapies.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that help predict metabolic disorders in patients treated with antipsychotics, enhancing patient care.
How similar studies have gone: While there is existing literature on the metabolic effects of antipsychotics, this specific approach of using transcriptomics to identify biomarkers is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 5-17 years; * group 1: antipsychotic users with metabolic disorders; * group 2: antipsychotic users without metabolic disorders; * group 3: non-antipsychotic users with metabolic disorders. The definition of antipsychotic use includes daily use for at least 3 months prior to enrollment. The definition of metabolic disorders includes: BMI-Z for age, sex and height \> +1 Waist circumference \> 90th percentile for age, sex and height Diastolic or systolic blood pressure \> 90th percentile for age, sex and height Fasting blood glucose \> 99 mg/dl Fasting triglycerides \> 149 mg/dl Fasting cholesterol \< 41 mg/dl. Patients with metabolic disorders are defined as those who meet at least one of the above criteria. Patients without metabolic disorders are defined as those who do not present any of the above criteria. Exclusion Criteria: * presence of diagnosed genetic conditions known to alter energy metabolism and/or nutrition; * presence of diagnosed eating disorders; * habitual use of supplements known to alter energy metabolism and/or nutrition; * concomitant use of drugs known to alter energy metabolism and/or nutrition.
Where it's running
-
IRCCS Eugenio Medea
Bosisio Parini, Lc, Italy Recruiting
Study contacts
- Study coordinator: Marco Pozzi, PhD
- Email: marco.pozzi@lanostrafamiglia.it
- Phone: 031877919
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding brain development in congenital hypothyroidism: comparing affected children, healthy controls, and mild thyroid conditions
This study tests how brain development in children with congenital hypothyroidism compares to similar children without the condition and to kids with a mild thyroid finding.
-
Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders
This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.
-
Grappling with Trauma: BJJ for First Responders
This program tests whether eight weeks of Brazilian Jiu-Jitsu can be tied to changes in trauma-related symptoms for first responders who prefer movement-based activities over traditional mental health services.
-
Melillo Method for kids with behavior and learning challenges
This pilot test will see if the Melillo Method can be feasibly delivered in two Illinois schools to help kids aged 8 and up who have behavioral and learning difficulties.
-
Therapy approaches for irritability in youths: active treatments vs nonactive psychoeducation
This study tests whether active psychotherapies for irritability in kids aged 8–16.5 years work better than nonactive, time-matched psychoeducation for children and their parents.
-
Understanding how sensory brain signals vary in people with and without neurodevelopmental disorders
This study tests whether people with neurodevelopmental disorders show more variation in brain responses to sensory stimulation than people without these disorders.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.